Welcome : Guest

PEDIATRIC DRUGS AND VACCINES - A GLOBAL STRATEGIC BUSINESS REPORT   

Research Abstract

This report analyzes the worldwide markets for Pediatric Drugs and Vaccines in US$ Million by the following Therapeutic Class: Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Anti-infective Drugs, CNS Drugs, and Other Pediatric Drugs. The Pediatric Vaccines market is also analyzed by the following Type: Combinations, Hepatitis, MMR, Varicella, Poliovirus, Pneumococcal, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 90 companies including many key and niche players such as -

Abbott Laboratories
Allergan, Inc.
Amgen, Inc.
AstraZeneca Plc
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company

Click here to request a full list of companies covered in the report...

Code: MCP-6503
Price: $4950
Companies: 90
Pages: 431
Date: June 2017
Market Data Tables: 128
  Status: * New Report



TABLE OF CONTENTS


  PEDIATRIC DRUGS AND VACCINES (Complete Report) Pages : 431   | $4950

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   Pediatrics: A Highly Underserved and Undervalued Group.....II-1 1$100
   Table 1: Global New Births (in Millions) per Annum by Geographic Region (includes corresponding Graph/Chart).....II-2

Table 2: Global Birth Rates: Number of Births (per ‘000 Population) for the Years 1990, 1995, 2000, 2005, 2010, and 2015 (includes corresponding Graph/Chart).....II-2
1$350
   Table 3: Top 25 Countries in Global Birth Rates Worldwide (2014): Ranked by Number of Births per 1000 Population (includes corresponding Graph/Chart).....II-31$350
   Table 4: Top 25 Countries in terms of Fertility Rates Worldwide (2014) - Ranked by Number of Children Born Per Woman (includes corresponding Graph/Chart).....II-41$350
   Pediatric Drugs Market – An Abode of Opportunities.....II-5
The United States: Largest Market for Pediatric Drugs and Vaccines.....II-5
1$100
   Developing Markets to Witness Faster Growth.....II-6
Table 5: Healthcare Spending as a Percentage of GDP by Region (2016E) (includes corresponding Graph/Chart).....II-6
1$350
   Table 6: Per-Capita Healthcare Expenditure in US$ for Select Countries/Regions (2014) (includes corresponding Graph/Chart).....II-7

Table 7: Developing Regions Lead Children Population Globally (includes corresponding Graph/Chart).....II-7
1$350
   Table 8: Global Under 15 Years Population (2016): Percentage Breakdown by Gender (includes corresponding Graph/Chart).....II-8

Table 9: Population of Children in the Age Group of 0-15 Years as a Percentage of Total Population by Region/Country (2016) (includes corresponding Graph/Chart).....II-8
1$350
   Table 10: Proportion of Children in the 0-15 Years Age Group by Country in Europe (2016) (includes corresponding Graph/Chart).....II-9

Table 11: Proportion of Children in the 0-15 Years Age Group by Country in Asia-Pacific (2016) (includes corresponding Graph/Chart).....II-9
1$350
   Table 12: Proportion of Children in the 0-15 Years Age Group by Country in Latin America (2016) (includes corresponding Graph/Chart).....II-10

Table 13: Proportion of Children in the 0-15 Years Age Group by Country in the Middle East (2016) (includes corresponding Graph/Chart).....II-10
Antibiotics: Largest Selling Drug Classes.....II-10
1$350
   Table 14: Global Pediatric Drugs Market by Therapeutic Class: Segments Ranked by Growth (includes corresponding Graph/Chart).....II-11
Pediatric Vaccines Market – On High Growth Trajectory.....II-11
1$350
   Supply and Demand Dynamics of the Global Vaccine Market.....II-12 1$100
   Table 15: Global Vaccine Market by Countries’ Economic Status (2016): Percentage Share Breakdown for High-income, Middle-Income (Upper & Lower), and Low-income Nations (includes corresponding Graph/Chart).....II-13
UNICEF Addresses BCG Vaccine Supply Shortage.....II-13
1$350
   Access to Vaccines Index: Aiding Increased Access to Vaccines.....II-14
Recent Advancements/Achievements in the Pediatric Vaccines Space.....II-14
1$100
   Pediatric Exclusivity Drives Manufacturers’ Interest.....II-15
Pediatric Exclusitivity Granted to Branded Drugs.....II-15
2$200
   New Product Approvals and Pipeline – A Key Growth Propeller.....II-17
Recent Pediatric Drug Approvals: 2015-2017.....II-17
1$100
   Pediatric Drug Approvals: 2011-2014.....II-181$100
   Phase III Completed Pediatric Drugs: 2015-2017 (As of July 2017).....II-191$100
   Ongoing Phase III Pediatric Drugs Clinical Trials: 2015-2017 (As of July
  2017).....II-20
1$100
   Potential for Pediatric Drugs Against Obesity-related Conditions.....II-21
Table 16: Top 10 Countries with the Highest Proportion of Overweight Children (includes corresponding Graph/Chart).....II-21
1$350
   List of Pediatric Drugs for Congestive Heart Failure Treatment .....II-221$100
   Recent Findings to Help Save Children’s Lives.....II-23
Challenges of Pediatric Drug Development: Formulation Problems and Ethical Constraints
  of Clinical Trials.....II-23
1$100
   Financial Enticement for Drug Makers to Conduct Dedicated Pediatric Trials.....II-241$100
   Modeling & Simulation – A Powerful Tool for Pediatric Clinical Study Sponsors.....II-251$100
   Pharmacometrics Approaches Gain Traction Among US and EU Researchers.....II-26
Challenges Associated with Adoption of Pharmacometric Approach.....II-26
1$100
   Guidelines for Conducting Ethically Correct Clinical Trials.....II-27
Pediatric Drug Market – Is Off-label Prescription Justified?.....II-27
1$100
   Indian Drug Manufacturers Develop Pneumococcal Conjugate Vaccine.....II-281$100
   High Vaccination Costs: A Major Hindrance for Pneumonia Vaccination.....II-291$100
   Vaccine Refusal by Parents – A Growing Trend in the US Market.....II-301$100
   Orphan Drugs for Pediatric Use Gain Popularity.....II-31
List of FDA Approved Orphan Drugs: 2015-2016.....II-31
1$100
   List of FDA Designated Orphan Drugs: 2015-2017.....II-322$200
   Pediatric Review Vouchers Foster Innovation in Rare Pediatric Drugs.....II-34
Need for Higher Focus on Fixed-Dose Combination for Pediatric HIV Infections.....II-34
1$100
   Approved Pediatric Antiretroviral Drugs for HIV Treatment.....II-35
Highly Fragmented Growth Hormone Market.....II-35
1$100
   Table 17: Number of Reported Cases for Vaccine-Preventable Diseases Globally: 2013-2016.....II-361$350
   Table 18: Percentage of Target Population Vaccinated, by Antigen: 2013-2015 (includes corresponding Graph/Chart).....II-371$350
   Immunization Coverage.....II-38
Table 19: Routine Immunization Coverage (2015): Percentage of Live Births/New Borns/Infants/ Children Vaccinated by Select Region.....II-38
1$350
   Market Share of Leading Pediatric Vaccine Manufacturers.....II-39
Table 20: Global Pediatric Vaccines Market by Leading Players (2016E): Percentage Market Share Breakdown of Dollar Sales for GlaxoSmithKline, Sanofi-Pasteur, Merck, Pfizer, and Others (includes corresponding Graph/Chart).....II-39
Phase III Completed Pediatric Vaccines: 2015-2017 (As of July 2017).....II-39
1$350
   Ongoing Phase III Pediatric Vaccines Clinical Trials: 2015-2017 (As of July
  2017).....II-40
Pediatric Vaccine Types.....II-40
Hemophilus Influenza Type B Vaccine.....II-40
1$100
   Available Hib and Combination Vaccines.....II-41
Diphtheria/Tetanus/Pertussis Vaccines (DTaP Vaccines).....II-41
1$100
   Available DTaP and Combination Vaccines.....II-42
Table 21: Global DTP3 Immunization Coverage: 2005-2015 (includes corresponding Graph/Chart).....II-42
1$350
   Table 22: DTP3 Immunization Coverage, 2015 (includes corresponding Graph/Chart).....II-43
Hepatitis A Vaccine.....II-43
Hepatitis B Vaccine.....II-43
1$350
   Hepatitis B Epidemiology.....II-44
Available Hepatitis A and B & Combination Vaccines.....II-44
Measles/Mumps/Rubella (MMR) Vaccines.....II-44
1$100
   Available MMR and Combination Vaccines.....II-45
Rotavirus Vaccines.....II-45
Available Rotavirus Vaccine.....II-45
Polio Vaccines.....II-45
1$100
   Available Polio and Combination Vaccines.....II-46
Varicella Virus Vaccine (VAR).....II-46
1$100
   Available Varicella Vaccines.....II-47
Pneumococcal Disease Vaccines.....II-47
1$100
   PCV 13 Replaces PCV 7.....II-48
Available Pneumococcal Conjugate Vaccine.....II-48
Meningococcal Vaccines.....II-48
1$100
   Available Meningococcal Polysaccharide and Combination vaccine.....II-49
Combination Vaccines.....II-49
1$100
   Hepatitis B Combination Vaccines to Propel Market Growth.....II-50 1$100
   Table 23: Number of Countries Having Introduced HepB Vaccine: 2005-2015 (includes corresponding Graph/Chart).....II-51

Table 24: Global Infant HepB3 Coverage: 2005-2015 (includes corresponding Graph/Chart).....II-51
Rising Women Workforce Propels Pediatric Vaccines Growth.....II-51
1$350
   Table 25: Female Employment-to-Population Ratio (%): 2002, 2007, 2012, & 2016 (includes corresponding Graph/Chart).....II-521$350
   Influenza.....II-53
Treatment.....II-53
1$100
   Urinary Tract Infection (UTI).....II-54
Prevalence.....II-54
Treatment.....II-54
Mumps.....II-54
1$100
   Complications Related to Mumps.....II-55
Prevention of Mumps in children.....II-55
Incidence.....II-55
Candidiasis.....II-55
Fifth Disease.....II-55
1$100
   Molluscum Contagiosum.....II-56
Roseola.....II-56
1$100
   Tetanus.....II-57
Whooping Cough.....II-57
Allergy and Respiratory Diseases.....II-57
1$100
   Prevalence Statistics.....II-58
The US.....II-58
Other Countries.....II-58
Diphtheria.....II-58
Incidence and Mortality Statistics.....II-58
1$100
   Upper Respiratory Infection (Common Cold).....II-59
Diagnosis & Treatment.....II-59
Measles.....II-59
1$100
   Statistics.....II-60
Asthma.....II-60
Prevalence.....II-60
1$100
   Central Nervous System Disorders.....II-61
Mental Disorders.....II-61
Prevalence.....II-61
Attention Deficit Hyperactivity Disorder.....II-61
Prevalence.....II-61
1$100
   Depression.....II-62
Prevalence.....II-62
Epilepsy.....II-62
1$100
   Epilepsy Treatment.....II-63
Incidence and Prevalence of Epilepsy in the US.....II-63
Hormonal Disorders.....II-63
Diabetes Mellitus.....II-63
1$100
   Hypothyroidism.....II-64
Hypothyroidism in Infants and Children.....II-64
Symptoms and Diagnosis.....II-64
1$100
   Treatment of Hypothyroidism in Children.....II-65
Precocious Puberty.....II-65
Symptoms and Signs.....II-65
Signs of Early Puberty in Girls and Boys.....II-65
1$100
   Treatment.....II-66
Hypopituitarism.....II-66
Treatment.....II-66
Lymphocytic Thyroiditis.....II-66
1$100
   Symptoms.....II-67
Treatment.....II-67
Other Diseases.....II-67
Cardiovascular Diseases.....II-67
Hypertension.....II-67
Causes of Hypertension in Children.....II-67
1$100
   Symptoms of High Blood Pressure.....II-68
Treatment.....II-68
Cancers.....II-68
Brain Tumors.....II-68
1$100
   Prevalence.....II-69
Leukemia.....II-69
Prevalence.....II-69
1$100
   Lymphomas.....II-70
Prevalence.....II-70
Retinoblastoma.....II-70
Prevalence.....II-70
1$100
   Ewing's Sarcoma.....II-71
Symptoms and Treatment.....II-71
1$100
   Prevalence.....II-72
Wilms' Tumor.....II-72
Stages and Treatment.....II-72
1$100
   Prevalence & Incidence.....II-73
Children's Rhabdomyosarcoma.....II-73
Symptoms and Signs.....II-73
1$100
   Treatment.....II-74
Statistics.....II-74
Neuroblastoma.....II-74
1$100
   Symptoms.....II-75
Treatment.....II-75
Osteogenic Sarcoma.....II-75
Prevalence.....II-75
1$100
   Symptoms and Treatment.....II-76
Diarrhea.....II-76
Inflammatory Bowel Disease (IBD).....II-76
Symptoms.....II-76
1$100
   Treatment.....II-77
Irritable Bowel Syndrome (IBS).....II-77
Causes & Symptoms.....II-77
Treatment.....II-77
1$100
   Pain.....II-78
Pain Control Medicines for Children.....II-78
Statistics.....II-78
Pain Statistics Among the American Children, General Population, and Other
  Adults.....II-78
Malaria.....II-78
1$100
   Anemia.....II-79
Treatment for Anemia in Children.....II-79
1$100
   List of Select FDA Approved Pediatric Drugs.....II-805$500
   Actelion Obtains "Epoprostenol Act" Label Extension for Pediatric PAH Patients in
  Japan.....II-85
FDA Approves Merck’s KEYTRUDA® (pembrolizumab).....II-85
Novartis Announces FDAs Acceptance of Company’s CAR-T Cell Therapy BLA for Pediatric
  and Young Adult Patients with r/r B-cell ALL.....II-85
Boehringer Ingelheim’s Tiotropium Respimat® Receives FDA Approval Expansion for
  Maintenance Treatment of Asthma in Children.....II-85
Sanofi Pasteur terminates a Vaccine Joint-venture with MSD.....II-85
1$100
   ViiV Healthcare Announces the Changed Opinion of CHMP to Lower the Age and Weight
  Limit for Tivicay® (dolutegravir) in Children and Adolescents Living with HIV in
    Europe.....II-86
Shire Announces FDA Approval of ADYNOVATE® [Antihemophilic Factor (Recombinant),
  PEGylated] for Use in Children and Surgical settings.....II-86
Pfizer Inc. Announces PHASE 3 TRIALs Positive Results of LYRICA® (PREGABALIN) Capsules
  CV and Oral Solution CV for Treating Pediatric Epilepsy Patients.....II-86
Pfizer’s Prevenar 13® Receives Approval for Use in Infants and Children in
  China.....II-86
Simponi® Receives European Commission Approval for Treatment of Polyarticular Juvenile
  Idiopathic Arthritis.....II-86
Sanofi Pasteur Launches India's first innovative 6-in-1 vaccine.....II-86
1$100
   Shire launches pediatric indication for immunodeficiency treatment HyQvia in
  Europe.....II-87
Novo Nordisk’s NovoRapid® receives positive opinion from CHMP for extended use in
  European Union for children as young as one year old.....II-87
Boehringer Ingelheim Announces the Ability of Tiotropium Respimat® for improving lung
  function in children aged 6-11.....II-87
FDA Approves BLINCYTO® (blinatumomab) for Use in Pediatric Patients with Philadelphia
   Chromosome-Negative Relapsed or Refractory B-cell Precursor Acute Lymphoblastic
    Leukemia.....II-87
FDA Approves Genentech’s Xolair® (omalizumab) for Allergic Asthma in Children.....II-87
Novartis Receives EU Approval for Revolade® as First-in-class Therapy for Children
  Aged 1 year and above with Chronic ITP.....II-87
1$100
   Pandemic Influenza Vaccine Receives Positive Opinion from CHMP.....II-88
GSK’s Advair® Diskus® Exhibits Primary Endpoint in paediatric ‘LABA’ Safety
  Study.....II-88
FDA Accepts Amgen's Supplemental Biologics License Application (sBLA) for The Expanded
   Use Of Enbrel® (Etanercept) To Treat Pediatric Patients with Chronic Severe
    Plaque Psoriasis.....II-88
Genentech’s supplemental Biologics License Application (sBLA) Receives Acceptance
  from FDA for reviewing Xolair® (omalizumab).....II-88
Shire Partner, Shionogi, Submits New Drug Application in Japan for ADHD treatment for
  children.....II-88
Shire Reports Topline Results from Phase 2 Studies in Children with Alagille
  Syndrome.....II-88
1$100
   FDA approves first drug to treat a rare enzyme disorder in pediatric and adult
  patients for Immediate Release.....II-89
Sanofi K.K. and Aptalis Pharmaceutical Technologies Launches Allegra Dry Syrup 5% in
  Japan.....II-89
Sanofi Pasteur Announces Availability of First Doses of Injectable Polio Vaccine
  ShanIPV(TM) in Near Future for Indian Infants.....II-89
Shire receives CHMP’s Positive Opinion in Europe for INTUNIV®.....II-89
Novo Nordisk’s Levemir® Receives Positive Opinion from CHMP for Extended use in
  Children as Young as one Year Old.....II-89
1$100
   Johnson & Johnson Acquires Actelion.....II-90
Sanofi Collaborates with MedImmune for development and Commercialization of
  Monoclonal Antibody for Preventing RSV.....II-90
GSK Intends to Opens a New Global Vaccines R&D Center in Rockville, MD, USA.....II-90
Lupin and Monosol Rx Enters into Licensing Agreement for Developing Multiple
  Pediatric-Focused Products.....II-90
ICGEB & Sun Pharma Enters into New Exclusive Collaboration to Develop Novel Dengue
  Vaccine for India & Global Markets.....II-90
1$100
   Actelion Initiates Phase III Study of Macitentan (Opsumit) for treating Children with
  PAH.....II-91
Shire and Cincinnati Children’s Establishes Rare Disease Research
  Collaboration.....II-91
1$100
   Abbott Laboratories (USA).....II-92
Allergan, Inc. (USA).....II-92
Amgen, Inc. (USA).....II-92
1$100
   AstraZeneca Plc. (UK).....II-93
Boehringer Ingelheim GmbH (Germany).....II-93
Bristol-Myers Squibb Company (USA).....II-93
1$100
   Eli Lilly and Company (USA).....II-94
F. Hoffmann-La Roche Ltd (Switzerland).....II-94
1$100
   Genentech, Inc. (USA).....II-95
GlaxoSmithKline plc. (UK).....II-95
Janssen Biologics B.V. (USA).....II-95
1$100
   Actelion Pharmaceuticals Ltd (Switzerland) (A Janssen Pharmaceutical
  Company).....II-96
Merck & Co., Inc. (USA).....II-96
1$100
   Novartis AG (Switzerland).....II-97
Novo Nordisk A/S (Denmark).....II-97
1$100
   Pfizer, Inc. (USA).....II-981$100
   Sanofi S.A (France).....II-99
Shionogi Inc. (USA).....II-99
1$100
   Shire Pharmaceuticals Group Plc. (UK).....II-1001$100
   Table 26: World Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....II-1011$350
   Table 27: World Historic Review for Pediatric Drugs and Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-1021$350
   Table 28: World 14-Year Perspective for Pediatric Drugs and Vaccines by Geographic Region - Percentage Share Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....II-1031$350
   Pediatric Vaccines Market by Therapeutic Segment.....II-104
Table 29: World Recent Past, Current & Future Analysis for Pediatric Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....II-104
1$350
   Table 30: World Historic Review for Pediatric Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-1051$350
   Table 31: World 14-Year Perspective for Pediatric Vaccines by Geographic Region - Percentage Share Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....II-1061$350
   Table 32: World Recent Past, Current & Future Analysis for Pediatric Hormones by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....II-1071$350
   Table 33: World Historic Review for Pediatric Hormones by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-1081$350
   Table 34: World 14-Year Perspective for Pediatric Hormones by Geographic Region - Percentage Share Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....II-1091$350
   Table 35: World Recent Past, Current & Future Analysis for Pediatric Allergy & Respiratory Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....II-1101$350
   Table 36: World Historic Review for Pediatric Allergy & Respiratory Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-1111$350
   Table 37: World 14-Year Perspective for Pediatric Allergy & Respiratory Drugs by Geographic Region - Percentage Share Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....II-1121$350
   Table 38: World Recent Past, Current & Future Analysis for Pediatric Antibiotics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....II-1131$350
   Table 39: World Historic Review for Pediatric Antibiotics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-1141$350
   Table 40: World 14-Year Perspective for Pediatric Antibiotics by Geographic Region - Percentage Share Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....II-1151$350
   Table 41: World Recent Past, Current & Future Analysis for Pediatric CNS Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....II-1161$350
   Table 42: World Historic Review for Pediatric CNS Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-1171$350
   Table 43: World 14-Year Perspective for Pediatric CNS Drugs by Geographic Region - Percentage Share Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....II-1181$350
   Table 44: World Recent Past, Current & Future Analysis for Other Pediatric Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....II-1191$350
   Table 45: World Historic Review for Other Pediatric Drugs by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....II-1201$350
   Table 46: World 14-Year Perspective for Other Pediatric Drugs by Geographic Region - Percentage Share Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....II-1211$350
   Table 47: World Recent Past, Current & Future Analysis for Pediatric Vaccines by Type - Combinations, Hepatitis, MMR, Varicella, Poliovirus, Pneumococcal, and Other Markets Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....II-1221$350
   Table 48: World 9-Year Perspective for Pediatric Vaccines by Type - Percentage Share Breakdown of Dollar Sales for Combinations, Hepatitis, MMR, Varicella, Poliovirus, Pneumococcal, and Other Markets for Years 2017 & 2024 (includes corresponding Graph/Chart).....II-1231$350
   A. Market Analysis.....III-1
Pediatric Drugs Market in the US.....III-1
Major Diseases Afflicting Children in the US.....III-1
Incidence of Diabetes Mellitus on Rise in the US.....III-1
Pediatric Vaccines Market.....III-1
1$75
   2017 Vaccine Recommendations Released by CDC and AAP.....III-21$75
   The United States Recommended Immunization Schedule for Children and Adolescents
  Aged 18 Years or Younger— United States, 2017......III-3
1$75
   The United States Catch-up immunization schedule for persons aged 4 months
  through 18 years who start late or who are more than 1 month behind—
    United States, 2017.....III-4
Dealing with Child Immunization and Parental Reluctance.....III-4
1$75
   Regulatory Environment.....III-5
Evolution of Regulations for Pediatric Drug Testing.....III-5
1$75
   PREA and BPCA – A Boon for Pharma Companies.....III-61$75
   Affordable Care Act Favoring the US Pediatric Drugs Market.....III-7
Child Population & Birth Rates.....III-7
Table 49: Birth Rates in the US: Breakdown of Number of Births (per ‘000 Population) for the Years 1990, 1995, 2000, 2005, 2010, and 2015 (includes corresponding Graph/Chart).....III-7
1$200
   Opportunity Indicator.....III-8
Table 50: Routine Immunization Coverage in the US (2013-2015): Percentage of Live Births/New Borns/Infants/Children Vaccinated (includes corresponding Graph/Chart).....III-8
Product Launches/Approvals.....III-8
2$200
   Strategic Corporate Developments.....III-101$75
   Focus on Select Major Players.....III-114$300
   B. Market Analytics.....III-15
Table 51: The US Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-15
1$200
   Table 52: The US Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-161$200
   Table 53: The US 14-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-171$200
   A. Market Analysis.....III-18
Opportunity Indicator.....III-18
Table 54: Canadian Routine Immunization Coverage (2013-2015): Percentage of Live Births/New Borns/Infants/Children Vaccinated (includes corresponding Graph/Chart).....III-18
1$200
   B. Market Analytics.....III-19
Table 55: Canadian Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-19
1$200
   Table 56: Canadian Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-201$200
   Table 57: Canadian 14-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-211$200
   A. Market Analysis.....III-22
Opportunity Indicator.....III-22
Table 58: Japanese Routine Immunization Coverage (2013-2015): Percentage of Live Births/New Borns/Infants/Children Vaccinated (includes corresponding Graph/Chart).....III-22
Product Launches/Approvals.....III-22
2$200
   B. Market Analytics.....III-24
Table 59: Japanese Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-24
1$200
   Table 60: Japanese Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-251$200
   Table 61: Japanese 14-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-261$200
   A. Market Analysis.....III-27
Table 62: Proportion of Children in the 0-15 Years Age Group by Country in Europe (2016) (includes corresponding Graph/Chart).....III-27
1$200
   Phase III Completed Clinial Trials for Pediatric Drugs: As of July 2014.....III-28
Pediatric Drugs in Phase III Clinical Trials: As of July 2014.....III-28
3$225
   Product Launches/Approvals.....III-311$75
   B. Market Analytics.....III-32
Table 63: European Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia, and Rest of European Markets Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-32
1$200
   Table 64: European Historic Review for Pediatric Drugs and Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia, and Rest of European Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-331$200
   Table 65: European 14-Year Perspective for Pediatric Drugs and Vaccines by Geographic Region - Percentage Share Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia, and Rest of European Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-341$200
   Table 66: European Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-351$200
   Table 67: European Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-361$200
   Table 68: European 14-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-371$200
   A. Market Analysis.....III-38
Opportunity Indicator.....III-38
Table 69: French Routine Immunization Coverage (2013-2015): Percentage of Live Births/New Borns/Infants/Children Vaccinated (includes corresponding Graph/Chart).....III-38
1$200
   Focus on Select Major Player.....III-391$75
   B. Market Analytics.....III-40
Table 70: French Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-40
1$200
   Table 71: French Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-411$200
   Table 72: French 14-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-421$200
   A. Market Analysis.....III-43
Opportunity Indicator.....III-43
Table 73: German Routine Immunization Coverage (2013-2015): Percentage of Live Births/New Borns/Infants/Children Vaccinated (includes corresponding Graph/Chart).....III-43
1$200
   Product Launches/ Approvals.....III-44
Select Major Player.....III-44
1$75
   B. Market Analytics.....III-45
Table 74: German Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-45
1$200
   Table 75: German Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-461$200
   Table 76: German 14-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-471$200
   A. Market Analysis.....III-48
Opportunity Indicator.....III-48
Table 77: Italian Routine Immunization Coverage (2013-2015): Percentage of Live Births/New Borns/Infants/Children Vaccinated (includes corresponding Graph/Chart).....III-48
1$200
   B. Market Analytics.....III-49
Table 78: Italian Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-49
1$200
   Table 79: Italian Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-501$200
   Table 80: Italian 14-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-511$200
   A. Market Analysis.....III-52
Opportunity Indicator.....III-52
Table 81: The UK and Northern Ireland Routine Immunization Coverage (2013-2015): Percentage of Live Births/New Borns/Infants/ Children Vaccinated (includes corresponding Graph/Chart).....III-52
1$200
   Product Launches/Approvals.....III-53
Focus on Select Major Players.....III-53
2$150
   B. Market Analytics.....III-55
Table 82: The UK Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-55
1$200
   Table 83: The UK Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-561$200
   Table 84: The UK 14-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-571$200
   A. Market Analysis.....III-58
Opportunity Indicator.....III-58
Table 85: Spanish Routine Immunization Coverage (2013-2015): Percentage of Live Births/New Borns/Infants/Children Vaccinated (includes corresponding Graph/Chart).....III-58
1$200
   B. Market Analytics.....III-59
Table 86: Spanish Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-59
1$200
   Table 87: Spanish Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-601$200
   Table 88: Spanish 14-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-611$200
   A. Market Analysis.....III-62
Opportunity Indicator.....III-62
Table 89: Russian Federation Routine Immunization Coverage (2013-2015): Percentage of Live Births/ New Borns/Infants/Children Vaccinated (includes corresponding Graph/Chart).....III-62
1$200
   B. Market Analytics.....III-63
Table 90: Russian Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-63
1$200
   Table 91: Russian Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-641$200
   Table 92: Russian 14-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-651$200
   A. Market Analysis.....III-66
Product Launches/ Approvals.....III-66
1$75
   Strategic Corporate Development.....III-67
Focus on Select Major Players.....III-67
3$225
   B. Market Analytics.....III-70
Table 93: Rest of Europe Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-70
1$200
   Table 94: Rest of Europe Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-711$200
   Table 95: Rest of Europe 14-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-721$200
   A. Market Analysis.....III-73
Table 96: Proportion of Children in the 0-15 Years Age Group by Country in Asia-Pacific (2016) (includes corresponding Graph/Chart).....III-73
Burgeoning Middle Class Population in Asia Bodes Well for Market Growth.....III-73
1$200
   Table 97: World Middle Class Population (2012 & 2030): Percentage Share Breakdown by Region - North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (includes corresponding Graph/Chart).....III-741$200
   B. Market Analytics.....III-75
Table 98: Asia-Pacific Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Geographic Region - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-75
1$200
   Table 99: Asia-Pacific Historic Review for Pediatric Drugs and Vaccines by Geographic Region - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-761$200
   Table 100: Asia-Pacific 14-Year Perspective for Pediatric Drugs and Vaccines by Geographic Region - Percentage Share Breakdown of Dollar Sales for China, India, and Rest of Asia-Pacific Markets for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-771$200
   Table 101: Asia-Pacific Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-781$200
   Table 102: Asia-Pacific Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-791$200
   Table 103: Asia-Pacific 14-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-801$200
   A. Market Analysis.....III-81
Chinese Market Outlook.....III-81
Opportunity Indicator.....III-81
Table 104: Chinese Routine Immunization Coverage (2013-2015): Percentage of Live Births/New Borns/Infants/Children Vaccinated (includes corresponding Graph/Chart).....III-81
1$200
   Growing Pediatric Market in China.....III-82
Table 105: Chinese Population (2000-2016): Breakdown of Population by Age Group (includes corresponding Graph/Chart).....III-82
China Sets Eyes on Supporting Pediatric Drugs Market.....III-82
1$200
   Expediting R&D and Drug Review Process.....III-83
Strengthening Policies Related to Pediatric Drug Production and Supply.....III-83
Enhancing Clinical Usage of Pediatric Drugs.....III-83
1$75
   Implementation of Safety and Quality Control Measures.....III-84
Harmonizing Chinese and Western Drugs.....III-84
Increasing Public Awareness.....III-84
Product Approval.....III-84
1$75
   B. Market Analytics.....III-85
Table 106: Chinese Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-85
1$200
   Table 107: Chinese Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-861$200
   Table 108: Chinese 14-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-871$200
   A. Market Analysis.....III-88
Opportunity Indicator.....III-88
Table 109: Indian Routine Immunization Coverage (2013-2015): Percentage of Live Births/New Borns/Infants/Children Vaccinated (includes corresponding Graph/Chart).....III-88
1$200
   Pediatric Drug Development in India.....III-89
Higher Usage of Pediatric Drugs than Vaccines in the Indian Market.....III-89
1$75
   Measles Rubella (MR) Vaccine Launched for Dual Protection in India.....III-901$75
   Three New Children Vaccines under India’s Universal Immunization Programme.....III-91
Product Launch/Approval.....III-91
Strategic Corporate Development.....III-91
1$75
   B. Market Analytics.....III-92
Table 110: Indian Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-92
1$200
   Table 111: Indian Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-931$200
   Table 112: Indian 14-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-941$200
   A. Market Analysis.....III-95
Opportunity Indicator.....III-95
Table 113: Routine Immunization Coverage in Republic of Korea (2013-2015): Percentage of Live Births/New Borns/Infants/Children Vaccinated (includes corresponding Graph/Chart).....III-95
1$200
   B. Market Analytics.....III-96
Table 114: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-96
1$200
   Table 115: Rest of Asia-Pacific Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-971$200
   Table 116: Rest of Asia-Pacific 14-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-981$200
   A. Market Analysis.....III-99
Table 117: Proportion of Children in the 0-15 Years Age Group by Country in Latin America (2016) (includes corresponding Graph/Chart).....III-99
1$200
   Opportunity Indicator.....III-100
Table 118: Brazilian Routine Immunization Coverage (2013-2015): Percentage of Live Births/New Borns/Infants/Children Vaccinated (includes corresponding Graph/Chart).....III-100
1$200
   B. Market Analytics.....III-101
Table 119: Latin American Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-101
1$200
   Table 120: Latin American Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-1021$200
   Table 121: Latin American 14-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-1031$200
   A. Market Analysis.....III-104
Africa.....III-104
Kenya Introduces Advanced Drugs for Treatment of TB in Children.....III-104
1$75
   Opportunity Indicator.....III-105
Table 122: Proportion of Children in the 0-15 Years Age Group by Country in the Middle East (2016) (includes corresponding Graph/Chart).....III-105

Table 123: Saudi Arabian Routine Immunization Coverage (2013-2015): Percentage of Live Births/New Borns/Infants/Children Vaccinated (includes corresponding Graph/Chart).....III-105
1$200
   Table 124: South African Routine Immunization Coverage (2013-2015): Percentage of Live Births/New Borns/Infants/Children Vaccinated (includes corresponding Graph/Chart).....III-106

Table 125: Central African Routine Immunization Coverage (2013-2015): Percentage of Live Births/New Borns/Infants/Children Vaccinated (includes corresponding Graph/Chart).....III-106
1$200
   B. Market Analytics.....III-107
Table 126: Rest of World Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart).....III-107
1$200
   Table 127: Rest of World Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart).....III-1081$200
   Table 128: Rest of World 14-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Share Breakdown of Dollar Sales for Pediatric Vaccines, Pediatric Hormones, Allergy & Respiratory Drugs, Antibiotics, CNS Drugs and Other Pediatric Drugs Market for Years 2011, 2017 & 2024 (includes corresponding Graph/Chart).....III-1091$200
  
Total Companies Profiled: 90 (including Divisions/Subsidiaries - 103)

Region/Country Players

The United States 53 Canada 3 Japan 7 Europe 33 France 3 Germany 1 The United Kingdom 6 Italy 1 Rest of Europe 22 Asia-Pacific (Excluding Japan) 7
Click here to request a full table of contents and more details on this project.